Table 5. Study characteristics.

RCT: randomized controlled trial; STEP: semaglutide treatment effect in people; OASIS: oral semaglutide treatment effect in people with obesity

Author (study ID)	Type	Study name	No.	Baseline	Study duration (weeks)	Study start year
Garvey et al. [12]	RCT	STEP 5	304	Adults with BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidities, without diabetes	104	2018
Kadowaki et al. [13]	RCT	STEP 6	401	Adults with BMI ≥27 with ≥2 weight-related comorbidities, or BMI ≥35 with ≥1 weight-related comorbidity	68	2019
Knop et al. [14]	RCT	OASIS 1	667	Adults with BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidities, without diabetes	68	2021
Kosiborod et al. [15]	RCT	-	529	Patients with heart failure with preserved ejection fraction and a BMI ≥30	52	2021
Mu et al. [16]	RCT	STEP 7	375	Adults with BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidity without or without T2D	44	2020
Rubino et al. [17]	RCT	STEP 4	902	Adults with ≥1 self-reported unsuccessful dietary effort to lose weight and with a BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidity	68	2018
Rubino et al. [18]	RCT	STEP 8	338	Adults with BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidities, without diabetes	68	2019
Wadden et al. [19]	RCT	STEP 3	611	Adults with BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidities, without diabetes	68	2018
Wilding et al. [20]	RCT	STEP 1	1961	Adults with BMI ≥30 or BMI ≥27 with ≥1 weight-related comorbidities, without diabetes	68	2018
Ghusn et al. [21]	Retrospective cohort	-	175	Adults with BMI ≥27 who were prescribed once-weekly semaglutide subcutaneously for ≥3 months	24	2021